Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-935 in Healthy Subjects

Next Previous
Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-935 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Soticlestat (Primary)
  • Indications Complex regional pain syndromes; Dravet syndrome; Epilepsy; Lennox-Gastaut syndrome; Myoclonic epilepsies; Tuberous sclerosis
  • Focus Adverse reactions; First in man
  • Sponsors Takeda

Most Recent Events

  • 09 Apr 2021 Results published in the British Journal of Clinical Pharmacology.
  • 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology.
  • 05 Dec 2017 Results presented at the 71st Annual Meeting of the American Epilepsy Society.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top